Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its position in C.R. Bard, Inc. (NYSE:BCR) by 12.3% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,951 shares of the medical instruments supplier’s stock after buying an additional 1,859 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in C.R. Bard were worth $5,358,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Fundsmith LLP boosted its stake in C.R. Bard by 2.1% in the first quarter. Fundsmith LLP now owns 2,553,141 shares of the medical instruments supplier’s stock worth $633,996,000 after buying an additional 52,272 shares in the last quarter. Buffington Mohr McNeal boosted its stake in C.R. Bard by 14.1% in the first quarter. Buffington Mohr McNeal now owns 7,545 shares of the medical instruments supplier’s stock worth $1,875,000 after buying an additional 930 shares in the last quarter. Chase Investment Counsel Corp boosted its stake in C.R. Bard by 13.7% in the first quarter. Chase Investment Counsel Corp now owns 8,614 shares of the medical instruments supplier’s stock worth $2,140,000 after buying an additional 1,038 shares in the last quarter. Credit Agricole S A boosted its stake in C.R. Bard by 2.8% in the first quarter. Credit Agricole S A now owns 89,102 shares of the medical instruments supplier’s stock worth $22,148,000 after buying an additional 2,425 shares in the last quarter. Finally, Ativo Capital Management LLC purchased a new stake in C.R. Bard during the first quarter worth $2,504,000. Institutional investors and hedge funds own 79.32% of the company’s stock.

Shares of C.R. Bard, Inc. (NYSE BCR) opened at 318.78 on Monday. C.R. Bard, Inc. has a one year low of $203.63 and a one year high of $323.27. The firm’s 50-day moving average price is $319.82 and its 200-day moving average price is $289.48. The firm has a market cap of $23.17 billion, a PE ratio of 41.85 and a beta of 0.59.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The company had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. During the same quarter in the prior year, the firm earned $2.54 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. Equities research analysts expect that C.R. Bard, Inc. will post $11.82 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were given a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. The ex-dividend date of this dividend was Thursday, July 20th. C.R. Bard’s dividend payout ratio is 13.67%.

ILLEGAL ACTIVITY NOTICE: This story was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://theolympiareport.com/2017/08/28/fjarde-ap-fonden-fourth-swedish-national-pension-fund-raises-stake-in-c-r-bard-inc-bcr.html.

BCR has been the topic of a number of analyst reports. BidaskClub cut C.R. Bard from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $342.00 target price on the stock in a report on Thursday, May 11th. Finally, BMO Capital Markets reiterated a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $285.67.

In other news, insider John P. Groetelaars sold 23,687 shares of the stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the sale, the insider now owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.80% of the stock is owned by corporate insiders.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.